The U.S. Department of Transportation has issued a final rule expanding DOT's current drug testing panel to include semi-synthetic opioids: hydrocodone, hydromorphone, oxymorphone and oxycodone on the required drug testing panel for DOT regulated industries. The drugs are more commonly known as OxyContin, Percodan, Percocet, Vicodin, Lortab, Norco, Dilaudid and Exalgo. Employees will no longer be tested for MDEA.
As required by the Omnibus Transportation Employee Testing Act of 1991, the DOT is harmonizing with the Department of Health and Human Services revised Mandatory Guidelines on Federal Testing Programs. The change will also clarify existing drug testing provisions, make technical amendments and removes the requirement for employers and Consortium/Third Party Administrators to submit blind specimens.
What employers need to know
The HHS certified labs performing DOT tests will make the change to all testing beginning on January 1, 2018. Employers with concerns should contact their collection locations or drug testing third party administrators for guidance.
Important Note: NON DOT tests are not affected by this change, however, in light of the current opiate abuse epidemic, we strongly recommend that all employers expand opiate testing to include the above listed drugs. To expand opiate testing, contact your drug testing provider.
If you have any questions regarding this change, please contact our offices.